Xenetic Biosciences Inc., of Lexington, Mass., said it was cleared by the FDA to start a phase II trial of Virexxa (sodium cridanimod), a small-molecule immunomodulator and interferon inducer, in conjunction with progestin therapy for the treatment of endometrial cancer in women with recurrent or persistent disease who have failed progestin monotherapy.